Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

(2023) Chantal Mathieu et al.   LANCET

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial

(2023) Athena Philis-Tsimikas et al.   Lancet Diabetes & Endocrinology

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2022) Melanie J. Davies et al.   DIABETES CARE

Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes

(2022) Athena Philis‐Tsimikas et al.   DIABETES OBESITY & METABOLISM

6. Glycemic Targets: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

(2022) Tadej Battelino et al.   Lancet Diabetes & Endocrinology

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

(2021) Erica Nishimura et al.   BMJ Open Diabetes Research & Care

Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)

(2021) William H. Polonsky et al.   Diabetes Therapy

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States

(2018) Reema Mody et al.   DIABETES OBESITY & METABOLISM

Clinical inertia to insulin initiation and intensification in the UK: A focused literature review

(2017) Kamlesh Khunti et al.   Primary Care Diabetes

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

(2013) Athena Philis-Tsimikas et al.   ADVANCES IN THERAPY

Better analyze the determinants of therapeutic inertia to overcome it

(2012) S. Halimi et al.   DIABETES & METABOLISM

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Patient perspectives on once-weekly medications for diabetes

(2010) W. H. Polonsky et al.   DIABETES OBESITY & METABOLISM